Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8 Puritas ≥99.5%

Description:

Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)

CAS: 486460-00-8

Puritas: ≥99.5% (HPLC)

Aspectus: Alba ad Off-White pulveris

Sitagliptin phosphate monohydratorum intermedium (CAS: 654671-77-9) diabete melliti tractatum.

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Supple Sitagliptin Phosphate Monohydratorum intermedia:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydratum API CAS 654671-77-9
Acidum trifluorophenylaceticum 2,4,5-
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydratum Intermediate CAS 486460-21-3

Chemical Properties:

Nomen chemicum	Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)
Synonyma	(R) -Sitagliptin N-Boc-Acid Impurity
CAS Number	486460-00-8
CATTUS Number	RF-PI1192
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C15H18F3NO4
M. Pondus	333.31
Liquescens punctum	136.0~ 138.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Lepidium sativum ab HPLC	Retentionis tempus Sample concordat cum Reference Standard
Damnum in Siccatio	≤0.50%
Cinis sulphated	≤0.50%
Metalla gravis	<20ppm
Isomer	≤0.50%
Substantiae cognatae
immunditiam A	≤0.50%
Alia alia immunditia	≤0.50%
Totalis immunditias	≤0.50%
Puritas	≥99.5% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	Sitagliptin Phosphate Monohydratorum medium (CAS: 654671-77-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum (CAS: 486460-00-8) medium magni momenti est ad parandum sitagliptinum.Sitagliptinphosphate est prima dipeptidase -IV(DPP-4) inhibitor a FDA in 2006 approbata. Ponitur pro curatione speciei II diabete melliti.Patet effectum hypoglycemicum cum solum vel coniuncte cum metformin et pioglitazone adhibitum, et tutum est cum paucis reactionibus adversantibus bene tolerari.Mense Augusto 2009 pharmacum ab Unione Europaea probatum est tamquam medicamentum primae lineae pro curatione speciei 2 diabete.Post 2011, aliae post aliae nationes phosphate sitagliptin et alpha glycosidasi inhibitores seu insulinum compositum probaverunt.Sitagliptin phosphas primus est FDA-approbatus dipeptidyl peptidase-IV inhibitor adhibendus in tractatione speciei 2 diabete longe, sub commercii nomine Januvia.